Two Sigma Advisers LP purchased a new stake in Audentes Therapeutics (NASDAQ:BOLD) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 16,500 shares of the biotechnology company’s stock, valued at approximately $516,000.
A number of other hedge funds also recently bought and sold shares of the stock. Goldman Sachs Group Inc. raised its stake in Audentes Therapeutics by 433.8% in the fourth quarter. Goldman Sachs Group Inc. now owns 80,097 shares of the biotechnology company’s stock valued at $2,503,000 after purchasing an additional 65,092 shares in the last quarter. Deutsche Bank AG raised its stake in Audentes Therapeutics by 227.9% in the fourth quarter. Deutsche Bank AG now owns 50,650 shares of the biotechnology company’s stock valued at $1,582,000 after purchasing an additional 35,201 shares in the last quarter. Farallon Capital Management LLC acquired a new position in Audentes Therapeutics in the fourth quarter valued at about $9,989,000. Tocqueville Asset Management L.P. acquired a new position in Audentes Therapeutics in the fourth quarter valued at about $448,000. Finally, Renaissance Technologies LLC acquired a new position in Audentes Therapeutics in the fourth quarter valued at about $1,672,000. 66.96% of the stock is owned by institutional investors and hedge funds.
A number of research analysts recently commented on the company. HC Wainwright set a $37.00 price target on Audentes Therapeutics and gave the company a “buy” rating in a research note on Friday, March 9th. Cowen reaffirmed a “buy” rating on shares of Audentes Therapeutics in a research note on Friday, March 9th. Zacks Investment Research upgraded Audentes Therapeutics from a “hold” rating to a “buy” rating and set a $37.00 target price on the stock in a research report on Thursday, March 8th. ValuEngine upgraded Audentes Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, April 4th. Finally, William Blair reiterated a “buy” rating on shares of Audentes Therapeutics in a research report on Friday, January 5th. Four analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $35.56.
Audentes Therapeutics (NASDAQ:BOLD) last released its earnings results on Thursday, March 8th. The biotechnology company reported ($0.82) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.91) by $0.09. sell-side analysts anticipate that Audentes Therapeutics will post -3.43 EPS for the current year.
In other news, major shareholder Orbimed Advisors Llc sold 421,638 shares of the business’s stock in a transaction dated Friday, March 2nd. The stock was sold at an average price of $35.17, for a total transaction of $14,829,008.46. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, VP Suyash Prasad sold 7,800 shares of the business’s stock in a transaction dated Thursday, March 29th. The stock was sold at an average price of $30.03, for a total value of $234,234.00. Following the sale, the vice president now owns 7,800 shares in the company, valued at $234,234. The disclosure for this sale can be found here. In the last quarter, insiders sold 1,138,107 shares of company stock worth $39,502,022. Company insiders own 47.30% of the company’s stock.
TRADEMARK VIOLATION WARNING: This report was originally posted by Week Herald and is the sole property of of Week Herald. If you are reading this report on another domain, it was illegally stolen and republished in violation of U.S. and international trademark & copyright legislation. The original version of this report can be accessed at https://weekherald.com/2018/04/20/two-sigma-advisers-lp-purchases-shares-of-16500-audentes-therapeutics-bold.html.
Audentes Therapeutics Profile
Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT982, which is in preclinical studies for the treatment of pompe disease; and AT307 that is in preclinical studies to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.
Want to see what other hedge funds are holding BOLD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Audentes Therapeutics (NASDAQ:BOLD).
Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.